Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Некоторые особенности консервативной патогенетической терапии в начальном периоде панкреонекроза
Некоторые особенности консервативной патогенетической терапии в начальном периоде панкреонекроза
В.А.Горский, М.А.Агапов, М.В.Хорева, А.С.Смирнова, И.В.Леоненко. Некоторые особенности консервативной патогенетической терапии в начальном периоде панкреонекроза. Consilium Medicum. Хирургия (Прил.). 2012; 2: 5-10.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Багненко С.Ф. Острый панкреатит – современное состояние проблемы и нерешенные вопросы. Под ред. С.Ф.Багненко, В.Р.Гольцова. АЛЬМАНАХ Института хирургии им. А.В.Вишневского. 2008; 3 (3): 104–12.
2. Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 1996; 24: 163–72.
3. Гельфанд Б.Р. Острый панкреатит. Под ред. Б.Р.Гельфанда, М.И.Филимонова, С.З.Бурневича и др. М., 2000.
4. Uhl W, Buchler MW, Malfertheiner P et al. A randomised, doubleblind, multicentretrial of octreotide in moderate to severe acute pancreatitis. Gut 1999; 45: 97–104.
5. Wisner JRJ, Renner IG, Grendell JH et al. Gabexate mesilate (FOY) protects against ceruletide-induced acute pancreatitis in the rat. Pancreas 1987; 2: 181–6.
6. Chen HM, Chen JC, Hwang TL et al. Prospective and randomized study of gabexate mesilate for the treatment of severe acute pancreatitis with organ dysfunction. Hepatogastroenterology 2000; 47: 1147–50.
7. Takeda K, Matsuno S, Sunamura M, Kakugawa Y. Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Am J Surg 1996; 171: 394–8.
8. Савельев ВС, Филимонов МИ, Гельфанд БР и др. Эволюция стерильного панкреонекроза при различных режимах антибактериальной профилактики и терапии. Cons. Med. Хирургия. 2002; 1: 26–8.
9. Dambrauskas Z, Gulbinas A, Pundzius J, Barauskas G. Meta-analysis of prophylactic parenteral antibiotic use in acute necrotizing pancreatitis. Medicina 2007; 43 (4): 291–300.
10. Mazaki T, Ishii Y, Takayama T. Meta-analysis of prophylactic antibiotic use in acute necrotizing pancreatitis. Br J Surg 2006; 93 (6): 674–84.
11. Dellinger EP, Tellado JM, Soto NE et al. Early Antibiotic Treatment for Severe Acute Necrotizing Pancreatitis: A Randomized, Double–Blind, Placebo–Controlled Study. Ann Surg 2007; 245 (5): 674–83.
12. Mayumi T, Takada T, Kawarada Y et al. Management strategy for acute pancreatitis in the JPN Guidelines. J hepato-biliary-pancreatic surg 2006; 13 (1):61–7.
13. Ortiz-Leyba C, Garnacho-Montero J. Saving lives in severe sepsis with the help of enteral nutrition. Crit care med 2007; 35 (3): 988–9; author reply 9–90.
14. Norman JG, Fink GW, Messina J et al. Timing of tumor necrosis factor antagonism is critical in determining outcome in murine lethal acute pancreatitis. Surg 1996; 120: 515–21.
15. Norman JG, Franz MG, Fink GS et al. Decreased mortality of severe acute pancreatitis after proximal cytokine blockade. Ann Surg 1995; 221: 625–31.
16. Kaw M, Singh S. Serum lipase, C-reactive protein and interleukin-6 levels in ERCP-induced pancreatitis. Gastrointest Endosc 2001; 54: 435–40.
17. McKay CJ, Curran F, Sharples C et al. Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis. Br J Surg 1997; 84: 1239–43.
18. Deviere J, Le Moine O, Van Laethem JL et al. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 2001; 120: 498–505.
19. Li Yu, Liantang Wang, Shangwu Chen. Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med 2010; 14 (11): 2592–603.
20. Erridge C. Endogenous ligands of TLR2 and TLR4: agonists or assistants? J Leukoc Biol 2010; 87 (6): 989–99.
21. Hidehiro S, Takashi U, Yoshifumi T et al. Role of Toll-like receptor 4 in the pathophysiology of severe acute pancreatitis in mice. Surg Today 2007; 37: 867–73.
22. Petrov MS, Windsor JA. Classification of the Severity of Acute Pancreatitis: How Many Categories Make Sense? Am J Gastroenterol 2010; 105: 74–6.
2. Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 1996; 24: 163–72.
3. Гельфанд Б.Р. Острый панкреатит. Под ред. Б.Р.Гельфанда, М.И.Филимонова, С.З.Бурневича и др. М., 2000.
4. Uhl W, Buchler MW, Malfertheiner P et al. A randomised, doubleblind, multicentretrial of octreotide in moderate to severe acute pancreatitis. Gut 1999; 45: 97–104.
5. Wisner JRJ, Renner IG, Grendell JH et al. Gabexate mesilate (FOY) protects against ceruletide-induced acute pancreatitis in the rat. Pancreas 1987; 2: 181–6.
6. Chen HM, Chen JC, Hwang TL et al. Prospective and randomized study of gabexate mesilate for the treatment of severe acute pancreatitis with organ dysfunction. Hepatogastroenterology 2000; 47: 1147–50.
7. Takeda K, Matsuno S, Sunamura M, Kakugawa Y. Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Am J Surg 1996; 171: 394–8.
8. Савельев ВС, Филимонов МИ, Гельфанд БР и др. Эволюция стерильного панкреонекроза при различных режимах антибактериальной профилактики и терапии. Cons. Med. Хирургия. 2002; 1: 26–8.
9. Dambrauskas Z, Gulbinas A, Pundzius J, Barauskas G. Meta-analysis of prophylactic parenteral antibiotic use in acute necrotizing pancreatitis. Medicina 2007; 43 (4): 291–300.
10. Mazaki T, Ishii Y, Takayama T. Meta-analysis of prophylactic antibiotic use in acute necrotizing pancreatitis. Br J Surg 2006; 93 (6): 674–84.
11. Dellinger EP, Tellado JM, Soto NE et al. Early Antibiotic Treatment for Severe Acute Necrotizing Pancreatitis: A Randomized, Double–Blind, Placebo–Controlled Study. Ann Surg 2007; 245 (5): 674–83.
12. Mayumi T, Takada T, Kawarada Y et al. Management strategy for acute pancreatitis in the JPN Guidelines. J hepato-biliary-pancreatic surg 2006; 13 (1):61–7.
13. Ortiz-Leyba C, Garnacho-Montero J. Saving lives in severe sepsis with the help of enteral nutrition. Crit care med 2007; 35 (3): 988–9; author reply 9–90.
14. Norman JG, Fink GW, Messina J et al. Timing of tumor necrosis factor antagonism is critical in determining outcome in murine lethal acute pancreatitis. Surg 1996; 120: 515–21.
15. Norman JG, Franz MG, Fink GS et al. Decreased mortality of severe acute pancreatitis after proximal cytokine blockade. Ann Surg 1995; 221: 625–31.
16. Kaw M, Singh S. Serum lipase, C-reactive protein and interleukin-6 levels in ERCP-induced pancreatitis. Gastrointest Endosc 2001; 54: 435–40.
17. McKay CJ, Curran F, Sharples C et al. Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis. Br J Surg 1997; 84: 1239–43.
18. Deviere J, Le Moine O, Van Laethem JL et al. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 2001; 120: 498–505.
19. Li Yu, Liantang Wang, Shangwu Chen. Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med 2010; 14 (11): 2592–603.
20. Erridge C. Endogenous ligands of TLR2 and TLR4: agonists or assistants? J Leukoc Biol 2010; 87 (6): 989–99.
21. Hidehiro S, Takashi U, Yoshifumi T et al. Role of Toll-like receptor 4 in the pathophysiology of severe acute pancreatitis in mice. Surg Today 2007; 37: 867–73.
22. Petrov MS, Windsor JA. Classification of the Severity of Acute Pancreatitis: How Many Categories Make Sense? Am J Gastroenterol 2010; 105: 74–6.
Авторы
В.А.Горский, М.А.Агапов, М.В.Хорева, А.С.Смирнова, И.В.Леоненко
ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава РФ, Москва
ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава РФ, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.